- Home
- SNTG vs CNSP Comparison
SNTG vs CNSP Comparison
Compare SNTG & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$4.98
Company Overview
Basic Information| Metric | SNTG | CNSP |
|---|---|---|
| Founded | 2009 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7M | 7.3M |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SNTG | CNSP |
|---|---|---|
| Price | $1.91 | $4.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | ★ 125.1K | 5.3K |
| Earning Date | 05-13-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.58 | $1.90 |
| 52 Week High | $12.70 | $10.59 |
Technical Indicators
Market Signals| Indicator | SNTG | CNSP |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 53.49 |
| Support Level | N/A | $4.58 |
| Resistance Level | N/A | $5.63 |
| Average True Range (ATR) | 0.00 | 0.33 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 0.00 | 51.94 |
Price Performance
Historical Comparison SNTG
CNSP
About SNTG Sentage Holdings Inc.
Sentage Holdings Inc is a financial service provider. The company offers a comprehensive range of financial services across consumer loan repayment and collection management, loan recommendation, and prepaid payment network services in China.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.